Drug intelligence / Profile preview

plasminogen, human-tvmh

Development stage
Approved
Lead developer
Kedrion Biopharma
Modality
Recombinant Proteins and Enzymes
Administration
intravenous
01

Overview

Plasminogen, human-tvmh (marketed as Ryplazim) is a plasma-derived human Glu-plasminogen concentrate indicated for the treatment of patients with plasminogen deficiency type 1 (hypoplasminogenemia). It is the first and only FDA-approved specific treatment for this ultra-rare genetic disorder, which is characterized by abnormally low plasminogen levels and activity, leading to the formation of fibrin-rich, ligneous pseudomembranous lesions on mucous membranes throughout the body. Ryplazim acts as a protein replacement therapy, temporarily restoring physiological plasminogen levels and re-establishing normal fibrinolytic activity to break down and resolve these lesions. It is administered intravenously.

Brand names
Ryplazim
Other names
Glu-plasminogenIV PLG concentratehuman plasma-derived Glu-plasminogenhuman plasma-derived plasminogenplasminogen (human)plasminogen, human-tvmh
02

Targets

Fibrin (Factor Ia)

Beyond the preview

Go deeper on plasminogen, human-tvmh.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on plasminogen, human-tvmh.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call